Information Provided By: 
Fly News Breaks for May 3, 2018
ONTX
May 3, 2018 | 08:46 EDT
As reported earlier, Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold with a price target of $3. The analyst notes that investors' focus is shifting to Rigosertib now that the company's "financing roadblock has been cleared". McCarthy believes that "Rigosertib could emerge as the first targeted therapy approved for MDS based on the mechanism of action and both prior and emerging data".
News For ONTX From the Last 2 Days
There are no results for your query ONTX
